PMID- 25026457
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20211021
IS  - 1473-1150 (Electronic)
IS  - 1470-269X (Linking)
VI  - 15
IP  - 1
DP  - 2015 Feb
TI  - EGFR ligands and DNA repair genes: genomic predictors of complete response after 
      capecitabine-based chemoradiotherapy in locally advanced rectal cancer.
PG  - 77-83
LID - 10.1038/tpj.2014.33 [doi]
AB  - Epidermal growth factor receptor (EGFR) activation by radiation leads to 
      increased cell proliferation and acts as a radioresistance mechanism. Neoadjuvant 
      chemoradiation is the standard of care for locally advanced rectal cancer, and to 
      date, no biomarkers of response have been found. We analyzed polymorphisms in the 
      EGFR and its ligands, DNA repair genes and the thymidylate synthase in 84 stages 
      II and III rectal cancer patients treated with neoadjuvant capecitabine plus 
      radiotherapy. The rs11942466 polymorphism in the amphiregulin (AREG) gene region 
      was associated with a pathological complete response (ypCR) (odds ratio: 0.26; 
      95% confidence interval: 0.06-0.79; P=0.014). The rs11615 C>T polymorphism in the 
      ERCC1 gene also correlated with the ypCR as no patients with a C/C genotype 
      achieved ypCR; P=0.023. This is the first work to propose variants within the 
      AREG and the ERCC1 genes as promising predictive biomarkers of ypCR in rectal 
      cancer.
FAU - Sebio, A
AU  - Sebio A
AD  - Department of Medical Oncology, Hospital de la Santa Ceu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain.
FAU - Salazar, J
AU  - Salazar J
AD  - 1] Department of Genetics, Hospital de la Santa Ceu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain [2] U-705 CIBERER, Barcelona, Spain.
FAU - Paez, D
AU  - Paez D
AD  - Department of Medical Oncology, Hospital de la Santa Ceu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain.
FAU - Berenguer-Llergo, A
AU  - Berenguer-Llergo A
AD  - IDIBELL-Institut Catala d'Oncologia, Barcelona, Spain.
FAU - Del Rio, E
AU  - Del Rio E
AD  - Department of Genetics, Hospital de la Santa Ceu i Sant Pau, Universitat Autonoma 
      de Barcelona, Barcelona, Spain.
FAU - Tobena, M
AU  - Tobena M
AD  - Department of Medical Oncology, Hospital de la Santa Ceu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain.
FAU - Martin-Richard, M
AU  - Martin-Richard M
AD  - Department of Medical Oncology, Hospital de la Santa Ceu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain.
FAU - Sullivan, I
AU  - Sullivan I
AD  - Department of Medical Oncology, Hospital de la Santa Ceu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain.
FAU - Targarona, E
AU  - Targarona E
AD  - Department of Surgery, Hospital de la Santa Ceu i Sant Pau, Universitat Autonoma 
      de Barcelona, Barcelona, Spain.
FAU - Balart, J
AU  - Balart J
AD  - Department of Radiotherapy, Hospital de la Santa Creu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain.
FAU - Baiget, M
AU  - Baiget M
AD  - 1] Department of Genetics, Hospital de la Santa Ceu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain [2] U-705 CIBERER, Barcelona, Spain.
FAU - Barnadas, A
AU  - Barnadas A
AD  - Department of Medical Oncology, Hospital de la Santa Ceu i Sant Pau, Universitat 
      Autonoma de Barcelona, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140715
PL  - United States
TA  - Pharmacogenomics J
JT  - The pharmacogenomics journal
JID - 101083949
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Ligands)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
CIN - Ann Transl Med. 2016 Dec;4(24):493. PMID: 28149855
CIN - Ann Transl Med. 2016 Dec;4(24):521. PMID: 28149883
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antimetabolites, Antineoplastic/therapeutic use
MH  - Capecitabine
MH  - Chemoradiotherapy/*methods
MH  - Cohort Studies
MH  - DNA Repair/*genetics
MH  - Deoxycytidine/*analogs & derivatives/therapeutic use
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - Fluorouracil/*analogs & derivatives/therapeutic use
MH  - Follow-Up Studies
MH  - Genetic Testing/methods
MH  - Genomics/methods
MH  - Humans
MH  - Ligands
MH  - Male
MH  - Middle Aged
MH  - Rectal Neoplasms/diagnosis/*genetics/*therapy
MH  - Treatment Outcome
EDAT- 2014/07/16 06:00
MHDA- 2015/09/29 06:00
CRDT- 2014/07/16 06:00
PHST- 2014/01/03 00:00 [received]
PHST- 2014/03/31 00:00 [revised]
PHST- 2014/05/22 00:00 [accepted]
PHST- 2014/07/16 06:00 [entrez]
PHST- 2014/07/16 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
AID - tpj201433 [pii]
AID - 10.1038/tpj.2014.33 [doi]
PST - ppublish
SO  - Pharmacogenomics J. 2015 Feb;15(1):77-83. doi: 10.1038/tpj.2014.33. Epub 2014 Jul 
      15.